XM无法为美国居民提供服务。
R
R

Regeneron


市场新闻

French and Benelux stocks-Factors to watch

French and Benelux stocks-Factors to watch Sept 16 (Reuters) - Below are company-related news and stories from France and Benelux which could have an impact on the region's markets or individual stocks. REXEL RXL.PA : QXO QXO.O , the company billionaire Brad Jacobs is seeking to launch into building services, recently made an offer of around $9.4 billion to acquire Rexel RXL.PA that the French company on Sunday said it had rebuffed .
R
R
S
F
N
U

US FDA approves Eli Lilly's drug for eczema

UPDATE 2-US FDA approves Eli Lilly's drug for eczema Adds details on disease in paragraph 3, patient population in paragraph 6, other treatments in paragraphs 7-8, details on drug in paragraphs 8-9 Sept 13 (Reuters) - Eli Lilly LLY.N said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above 12 years old.
P
R
S

Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product

BRIEF-Regeneron and Sanofi win another U.S regulatory approval for their Dupixent product Sept 13 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O /SANOFI SASY.PA : DUPIXENT® (DUPILUMAB) APPROVED IN THE U.S. AS FIRST AND ONLY TREATMENT FOR ADOLESCENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) Regeneron Pharmaceuticals and Sanofi today announced that the U.S.
R
S

Sanofi: Dupixent Meets Primary Endpoints In ADEPT pivotal study in BP

BRIEF-Sanofi: Dupixent Meets Primary Endpoints In ADEPT pivotal study in BP Sept 11 (Reuters) - Sanofi SA SASY.PA : DUPIXENT IS THE FIRST AND ONLY BIOLOGIC TO ACHIEVE SIGNIFICANT IMPROVEMENTS IN DISEASE REMISSION AND SYMPTOMS IN BULLOUS PEMPHIGOID POSITIVE PIVOTAL STUDY STUDY MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN ADULTS WITH MODERATE-TO-SEVERE DISEASE FIVE TIMES MORE PATIENTS ACHIEVED SUSTAINED DISEASE REMISSION WITH DUPIXENT THAN PLACEBO STUDY WILL SUPPORT REGULATORY SUBMISSIONS AROUND
R
S

U.S. Exlservice Holdings, Steel Dynamics, US Steel

U.S. RESEARCH ROUNDUP-Exlservice Holdings, Steel Dynamics, US Steel Sept 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Exlservice Holdings, Steel Dynamics and U.S. Steel Corp, on Monday. HIGHLIGHTS * Essex Property Trust Inc ESS.N : BMO raises target price to $310 from $294 * Exlservice Holdings Inc EXLS.O : Jefferies raises to buy from hold * Steel Dynamics Inc STLD.O : JP Morgan raises to neutral from underweig
C
R
S
U
E
U
C
C
H
U

Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 12:01 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +3.2% Dollar Tree Inc DLTR.OQ +2.3% Amazon.com Inc AMZN.OQ +2.1% Comcast Corp CMCSA.OQ +1.6% Arm Holdings PLC ARM.OQ +1.2% Bottom Performers Percent Change Copart Inc CPRT.OQ -7.1% Old Dominion Freight Line Inc ODFL.OQ -6.8% AstraZeneca PLC AZN.OQ -3.5% Vertex Pharmaceuticals Inc VRTX.OQ -3.1% Regeneron Pharmaceuticals Inc REGN.OQ -3.0% The Nasdaq 100 .NDX lost 9
A
A
C
R
T
V
D
U
C
O

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Arm Holdings PLC ARM.OQ +6.0% PDD Holdings Inc PDD.OQ +5.1% MongoDB Inc MDB.OQ +3.8% PayPal Holdings Inc PYPL.OQ +3.8% Atlassian Corp TEAM.OQ +3.7% Bottom Performers Percent Change Dollar Tree Inc DLTR.OQ -9.9% NVIDIA Corp NVDA.OQ -5.4% Warner Bros Discovery Inc WBD.OQ -2.8% Regeneron Pharmaceuticals Inc REGN.OQ -1.9% Copart Inc CPRT.OQ -1.5% The Nasdaq 100 .NDX gained 8.92 points
N
P
R
D
U
A
P
C

U.S. Advance Auto Parts, Chewy, Workday

U.S. RESEARCH ROUNDUP-Advance Auto Parts, Chewy, Workday Aug 23 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Advance Auto Parts, Chewy and Workday, on Friday. HIGHLIGHTS * Advance Auto Parts Inc AAP.N : JP Morgan cuts target price to $43 from $55 * Chewy CHWY.N : Piper Sandler raises to overweight from neutral * Intuit Inc INTU.O : Jefferies raises target price to $790 from $770 * Williams-Sonoma Inc WSM.N : TD Co
A
A
A
B
I
J
N
N
R
R
H
A

US FDA declines to approve Regeneron's blood cancer therapy

UPDATE 1-US FDA declines to approve Regeneron's blood cancer therapy Adds details from paragraph 2 onward Aug 20 (Reuters) - The U.S. Food and Drug Administration has declined to approve Regeneron's REGN.O therapy for a common form of blood cancer, the company said on Tuesday. Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment.
R

US FDA declines to approve Regeneron's blood cancer therapy

US FDA declines to approve Regeneron's blood cancer therapy Aug 20 (Reuters) - The U.S. Food and Drug Administration declined to approve Regeneron's REGN.O therapy for a common form of blood cancer, the company said on Tuesday. Reporting by Bhanvi Satija, Sneha S K and Nilutpal Timsina in Bengaluru; Editing by Shailesh Kuber
R

Regeneron Says FDA Issues Complete Response Letter For Co's Linvoseltamab

BRIEF-Regeneron Says FDA Issues Complete Response Letter For Co's Linvoseltamab Aug 20 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PROVIDES UPDATE ON BIOLOGICS LICENSE APPLICATION FOR LINVOSELTAMAB REGENERON PHARMACEUTICALS INC - FDA ISSUES COMPLETE RESPONSE LETTER FOR REGENERON'S LINVOSELTAMAB REGENERON PHARMACEUTICALS INC - LINVO
R

Regeneron climbs on Q2 results beat

BUZZ-Regeneron climbs on Q2 results beat ** Drugmaker Regeneron's REGN.O shares rise ~1.8% to $1,098.47 ** Co reports Q2 adj. profit of $11.56/shr vs est. of $10.61/shr - LSEG data ** Posts quarterly revenue of $3.55 bln vs est. of $3.38 bln ** Stock up 25% YTD Reporting by Christy Santhosh
R

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $11.56​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $10.24. The mean expectation of twenty four analysts for the quarter was for earnings of $10.61 per share.
R

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S

Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6

BRIEF-Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6 Aug 01 (Reuters) - Regeneron Q2 EPS USD 12.41. Q2 revenue USD 3,550 million vs. IBES estimate USD 3,379 million outlook FY capex USD 750-820 million
R

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M

Cencora raises annual profit forecast on strong demand for specialty medicines

Cencora raises annual profit forecast on strong demand for specialty medicines July 31 (Reuters) - Cencora COR.N raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer. The drug distributor also beat Wall Street estimates for third-quarter profit and revenue helped by strength in its U.S.
R

Regeneron Pharmaceuticals Inc <REGN.OQ> expected to post earnings of $10.61 a share - Earnings Preview

Regeneron Pharmaceuticals Inc expected to post earnings of $10.61 a share - Earnings Preview Regeneron Pharmaceuticals Inc REGN.OQ REGN.O is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Tarrytown New York-based company is expected to report a 7.0% increase in revenue to $3.379 billion from $3.16 billion a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
R

BioNTech rises after cancer therapy meets goal in mid-stage study

REFILE-BUZZ-BioNTech rises after cancer therapy meets goal in mid-stage study Corrects to add "$" sign in first bullet ** U.S. listed shares of BioNTech 22UAy.DE , BNTX.O rise 2.17% to $88.49 ** Co says its experimental mRNA cancer immunotherapy BNT111 in combination with Regeneron's REGN.O cancer drug Libtayo met the main goal in a mid-stage trial
P
R

Sanofi lifts 2024 profit forecast on strength in Dupixent, new products

UPDATE 2-Sanofi lifts 2024 profit forecast on strength in Dupixent, new products Adds share movement and analyst comment in paragraph 3, background on Roche and AstraZeneca in paragraph 4 By Manas Mishra July 25 (Reuters) - Sanofi SASY.PA on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter results beat estimates.
A
R
S



商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明